Why Biocryst Is A High-Risk High-Reward Stock
Shares of BioCryst (NASDAQ:BCRX) have been volatile. Shares have traded as low as $5.72 to over $6.70 in the last seven sessions.
The option premium for both calls and puts is running higher than normal. The reason, investors are expecting Phase 2 trial results for BCX7353, a drug focused on the elimination of angioedema attacks in patients with hereditary angioedema to be released anytime now.
The option premium for both calls and puts is running higher than normal. The reason, investors are expecting Phase 2 trial results for BCX7353, a drug focused on the elimination of angioedema attacks in patients with hereditary angioedema to be released anytime now.